United Therapeutics UTHR Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.17B+5.9% | $3.18B+10.6% | $3.13B+13.5% | $3.08B+17.6% | $2.99B+19.8% | ||
| $425.3M+29.2% | $384.4M+24.1% | $356.9M+17.1% | $339.1M+16.2% | $329.3M+18.4% | ||
| $2.74B+3.0% | $2.8B+9.0% | $2.77B+13.1% | $2.74B+17.8% | $2.66B+20.0% | ||
| 86.6%-2.4pp | 87.9%-1.3pp | 88.6%-0.3pp | 89%+0.1pp | 89%+0.1pp | ||
| $539.2M+2.5% | $550M+14.3% | $544.3M+9.2% | $520.3M+8.4% | $525.9M+22.5% | ||
| $769.8M+4.7% | $755.8M+6.5% | $733.7M+9.0% | $770.3M+32.4% | $735.4M+37.7% | ||
| $1.73B+9.0% | $1.69B+12.6% | $1.63B+10.7% | $1.63B+20.4% | $1.59B+28.1% | ||
| $1.44B+2.3% | $1.49B+8.4% | $1.49B+16.7% | $1.45B+14.6% | $1.4B+11.7% | ||
| 45.3%-1.6pp | 46.9%-1.0pp | 47.7%+1.3pp | 47%-1.2pp | 46.9%-3.4pp | ||
| $16.4M-54.1% | $19.5M-54.5% | $24.3M-51.5% | $31.4M-43.5% | $35.7M-39.3% | ||
| $173.2M+8.0% | $221.4M+36.7% | $172.9M+9.1% | $168.9M+22.6% | $160.4M+29.1% | ||
| $1.61B+2.9% | $1.71B+11.4% | $1.67B+15.9% | $1.62B+15.4% | $1.56B+13.2% | ||
| $321.3M-9.0% | $379.2M+10.3% | $394.7M+20.7% | $374.9M+13.0% | $353.2M+6.9% | ||
| $1.29B+6.3% | $1.33B+11.7% | $1.27B+14.5% | $1.24B+16.1% | $1.21B+15.2% | ||
| 40.6%+0.2pp | 41.9%+0.4pp | 40.7%+0.3pp | 40.4%-0.5pp | 40.4%-1.6pp | ||
| $27.08+8.0% | $27.89+13.3% | $26.41+16.1% | $25.64+18.0% | $25.08+18.8% | ||
| $1.52B+2.9% | $1.58B+8.9% | $1.58B+17.1% | $1.53B+15.4% | $1.48B+12.9% | ||
| 48.1%-1.4pp | 49.6%-0.8pp | 50.4%+1.5pp | 49.6%-1.0pp | 49.5%-3.0pp | ||
| $1.44B+2.3% | $1.49B+8.4% | $1.49B+16.7% | $1.45B+14.6% | $1.4B+11.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is United Therapeutics's revenue?
- United Therapeutics (UTHR) generated $3.2B in revenue over the trailing twelve months, up 5.9% year over year.
- Is United Therapeutics profitable?
- United Therapeutics reported $1.3B in net income over the trailing twelve months, a 40.6% net margin.
- What are United Therapeutics's profit margins?
- Gross margin is 86.6% and operating margin is 45.3%, with a 40.6% net margin.
- What is United Therapeutics's earnings per share?
- United Therapeutics's diluted EPS over the trailing twelve months is $27.08.
- Where does United Therapeutics's income statement data come from?
- Every line is extracted from United Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
